Latest Breaking News On - Episode definition - Page 1 : comparemela.com
federalregister.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from federalregister.gov Daily Mail and Mail on Sunday newspapers.
Here Are The 298 Costliest Rules In The New Unified Agenda Of Federal Regulations
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
[1] the HHS Office of Inspector General (OIG) said Visiting Nurse Association of Maryland (VNA) received overpayments of $2.1 million in 2015 and 2016. OIG audited a stratified random sample of 100 claims and found errors on 19 of them. As a result, VNA received overpayments of $25,295 for services provided in 2015 and 2016. “On the basis of our sample results, we estimated that VNA received overpayments of at least $2.1 million for the audit period,” according to OIG, which noted all the claims are outside the reopening period. OIG said VNA billed for services provided to beneficiaries who weren’t homebound or delivered services that were inconsistent with the plan of care, among other errors. VNA disagreed with most of OIG’s findings. In a letter to OIG, the home health agency said, “VNA stands firm that it was providing covered services,” and “the error rate does not support extrapolation.”
Below is Alston & Bird’s
Health Care Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.
Week in Review Highlight of the Week:
This week, CMS released its FY 2022 Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Rates Proposed Rule. Read more about the rule and other news below.
I. Regulations, Notices & Guidance
On April 26, 2021, the Food and Drug Administration (FDA) issued guidance entitled,
Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases; Draft Guidance for Sponsor-Investigators. FDA is publishing this draft guidance to help sponsor-investigators with developing the nonclinical information that FDA recommends to support an investigational new drug application (IND) for certain individual